Results 61 to 70 of about 83,436 (250)
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj +23 more
wiley +1 more source
Therapeutic Extracellular Vesicles from Synovial Fibroblast‐Primed MSCs for Osteoarthritis Treatment
EVs derived from the microenvironment of SFs transferred MSCs (miSF‐MSC‐EVs) enhanced the expression of miRNAs that regulate cell migration, cell adhesion, and the TGF‐β signaling pathway, demonstrating superior anti‐inflammatory and cartilage regeneration effects compared to conventional MSC‐EVs.
Seo Jeong Kim +5 more
wiley +1 more source
Peritoneal carcinomatosis is a hard‐to‐treat spread of abdominal cancers that often returns after therapy. Nanoparticles were developed to retain an immune‐boosting drug in the abdomen. When combined with chemotherapy in mice, this approach eliminated tumors in many cases and prevented recurrence, helping the immune system mount a stronger, longer ...
Vanessa Chan +10 more
wiley +1 more source
Necroptosis in Immuno-Oncology and Cancer Immunotherapy
Immune-checkpoint blockers (ICBs) have revolutionized oncology and firmly established the subfield of immuno-oncology. Despite this renaissance, a subset of cancer patients remain unresponsive to ICBs due to widespread immuno-resistance.
Jenny Sprooten +10 more
doaj +1 more source
Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative. [PDF]
Many cancer types are serious diseases causing mortality, and new therapeutics with improved efficacy and safety are required. Immuno-(cell)-therapy is considered as one of the promising therapeutic strategies for curing intractable cancer. In this study,
Keum-Joo Son +5 more
doaj +1 more source
(A) Isolation and purification of LDNVs. (B) Establishment of the ALI model and LDNVs delivery. (C) Therapeutic mechanisms of LDNVs in treating ALI. This scheme figure was drawn by Figdraw, ID: IUIIO21222. ABSTRACT Acute lung injury (ALI) is a lethal respiratory disease.
Xi Lin +10 more
wiley +1 more source
Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment
Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley +1 more source
eIF2α phosphorylation is pathognomonic for immunogenic cell death [PDF]
The phosphorylation of eIF2α is essential for the endoplasmic reticulum (ER) stress response, the formation of stress granules, as well as macroautophagy. Several successful anticancer chemotherapeutics have the property to induce immunogenic cell death (ICD), thereby causing anticancer immune responses.
Bezu L +12 more
openaire +2 more sources
Targeting cancer‐associated fibroblasts (CAFs) with fibroblast activation protein (FAP)‐directed nanoprobes for multimodal imaging and photothermal remodeling of the immunosuppressive microenvironment to enhance immunotherapy in triple‐negative breast cancer (TNBC).
Ling Zhan +6 more
wiley +1 more source
FDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death
Receptor-interacting serine/threonine kinase 1 (RIPK1) is a pivotal protein controlling cell death and inflammation. RIPK1 is an attractive therapeutic target, given that the inhibition of RIPK1 kinase activity has been shown to be effective in animal ...
Byeong-Ju Kim +13 more
doaj +1 more source

